Skin Reactions From Bipolar Drug Oxcarbazepine Emerge Early, Case Series Finds

A rare but clinically important side effect of a widely used mood-stabilizing drug has come into sharper focus. Researchers at the Affiliated Guangdong Second Provincial General Hospital of Jinan University in Guangzhou, China, have compiled one of the most detailed pictures to date of skin reactions linked to oxcarbazepine, a second-generation antiepileptic medication that psychiatrists increasingly reach for when treating bipolar disorder. In a retrospective case series published in BMC Psychiatry, the team led by first authors Yinghua Huang and Kunxi Xue documented twelve patients with bipolar disorder who developed cutaneous reactions while taking the drug, and their findings carry a clear practical message: the danger window opens early, often within the first two weeks of treatment.

Oxcarbazepine, often abbreviated OXC, is a chemical cousin of carbamazepine, one of the classic antiepileptic drugs that also established itself as a mainstay in the treatment of bipolar disorder. Structurally, oxcarbazepine is a keto analogue of carbamazepine, and it exerts its therapeutic effects primarily through its active metabolite, 10-hydroxycarbazepine, known as the monohydroxy derivative or MHD. This metabolite stabilizes hyperexcited neuronal membranes by blocking voltage-gated sodium channels, dampening the aberrant electrical firing that underlies both seizures and, in the psychiatric context, the pathological mood swings of mania. Because oxcarbazepine avoids some of the metabolic pitfalls of its parent compound, including the formation of reactive epoxide metabolites that have been implicated in carbamazepine hypersensitivity, clinicians have hoped it would offer a gentler profile. It is generally prescribed in selected clinical settings as an alternative or adjunctive option for patients with bipolar disorder who cannot tolerate first-line agents or who need additional mood stabilization.

Yet the skin remains a vulnerable organ system for this entire drug family. Antiepileptic drugs as a class are notorious for cutaneous adverse reactions, ranging from benign morbilliform rashes to the terrifying end of the spectrum occupied by severe cutaneous adverse reactions, or SCARs. These include Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms, known as DRESS. Stevens-Johnson syndrome and toxic epidermal necrolysis represent a continuum of the same disease process, in which an immune-mediated attack causes keratinocytes to die and the epidermis to separate from the dermis, producing blistering, skin sloughing, and mucosal involvement that can be life-threatening. Mortality in toxic epidermal necrolysis can reach double digits despite intensive care, and severity is often gauged with tools such as the SCORTEN score, while drug causality is assessed with instruments like the ALDEN algorithm and the RegiSCAR criteria. Against this backdrop, any report of skin reactions to oxcarbazepine deserves careful attention, particularly because reports describing OXC-associated cutaneous reactions specifically in patients with bipolar disorder have remained limited.

The Guangzhou team approached the problem with a retrospective descriptive design, combing through clinical records to identify twelve patients with bipolar disorder who had developed cutaneous reactions attributed to oxcarbazepine. The study was approved by the Medical Ethics Committee of the Affiliated Guangdong Second Provincial General Hospital of Jinan University, and written informed consent was obtained from all patients or their legal guardians. For each case, the researchers collected demographic characteristics, details of the medication regimen, the clinical features of the skin eruption, and the treatment outcomes. The diagnosis of bipolar disorder was established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, ensuring a diagnostically homogeneous cohort in which the drug, rather than diagnostic heterogeneity, was the variable of interest.

The timing of the reactions emerged as one of the most striking patterns in the data. Onset of cutaneous reactions occurred mainly within the first two weeks of treatment, a temporal signature that mirrors what is known about hypersensitivity reactions to aromatic antiepileptic drugs generally. This early window matters enormously for clinical practice, because it defines the period during which patients and their families need to be most vigilant. A rash appearing in the first fortnight of oxcarbazepine therapy should never be dismissed as a trivial irritation; it demands prompt evaluation and, in many cases, immediate discontinuation of the drug. The two-week signal also aligns with the immunology of delayed-type drug hypersensitivity, in which sensitization to a drug or its metabolites typically requires days to weeks before T-cell-mediated pathology becomes clinically visible on the skin.

In terms of presentation, the most common form was a generalized eruption, meaning a rash spreading across large areas of the body, followed by localized eruptions confined to specific regions. One patient among the twelve was diagnosed with Stevens-Johnson syndrome, the severe blistering disorder that constitutes a dermatological emergency. That single case is the most sobering element of the series, a reminder that even a drug marketed partly on its improved tolerability can, in susceptible individuals, trigger the full machinery of a severe cutaneous adverse reaction. The patient with Stevens-Johnson syndrome was among three patients in the series who were receiving lamotrigine concurrently, and the authors note that mixed drug attribution could not be excluded in these cases. Lamotrigine itself carries a well-known risk of severe skin reactions, particularly when titrated rapidly, so the presence of both drugs complicates the causal picture and illustrates a perennial challenge in psychopharmacology: patients with bipolar disorder frequently take combinations of medications, and disentangling which agent is responsible for an adverse event requires careful pharmacovigilance.

The good news from the series is that the outcomes were favorable. Clinical improvement was observed after discontinuation of oxcarbazepine and supportive management, a pattern consistent with the natural history of most drug-induced cutaneous reactions, which typically resolve once the offending agent is cleared. Supportive management for severe reactions can involve wound care, fluid and electrolyte management, pain control, and in the most serious cases interventions such as intravenous immunoglobulin, though the source material does not specify which supportive measures were used in individual patients. The essential clinical algorithm, however, is clear: early recognition, immediate drug withdrawal, and supportive care form the backbone of treatment for antiepileptic-induced skin reactions, and the Guangzhou experience reinforces that approach in the specific context of bipolar disorder.

The authors are appropriately cautious about what their study can and cannot show. With only twelve patients, a retrospective design, and no comparison group, the findings must be interpreted descriptively. They cannot be used to estimate the true incidence of oxcarbazepine-associated skin reactions, to establish causality with certainty, or to identify independent risk factors for developing them. Retrospective case series are hypothesis-generating by nature; they map the terrain of a clinical problem without quantifying its frequency. The researchers explicitly call for larger prospective studies to further characterize these reactions, work that would ideally include systematic skin assessment at defined time points, pharmacogenomic testing, and comparison groups of patients taking oxcarbazepine without reactions. Such studies could eventually clarify whether known genetic risk factors for carbamazepine hypersensitivity, such as certain human leukocyte antigen alleles, also predispose patients to oxcarbazepine reactions, a question of intense interest given the structural relationship between the two drugs.

For clinicians treating bipolar disorder, the practical takeaways are nonetheless actionable today. Oxcarbazepine remains a legitimate option in selected patients, but prescribers should counsel patients explicitly about skin symptoms before the first prescription, emphasizing that any rash, blistering, mucosal ulceration, or fever with skin changes in the first weeks of therapy warrants urgent medical contact. The first two weeks deserve heightened vigilance, and concomitant lamotrigine should prompt extra caution in attribution and monitoring. For patients, the study is a reminder that psychiatric medications, like all drugs, carry physical as well as psychological side effects, and that the skin can serve as an early warning system. For researchers, the twelve cases from Guangzhou provide a descriptive foundation on which larger, prospective investigations can now build, moving the field from anecdote toward the incidence estimates and risk-factor profiles that would allow truly personalized prescribing decisions in bipolar disorder.

Subject of Research: Cutaneous adverse reactions associated with oxcarbazepine treatment in patients with bipolar disorder

Article Title: Clinical features of oxcarbazepine-associated cutaneous reactions in patients with bipolar disorder: a retrospective case series

Article References: Huang, Y., Xue, K., Fan, C., Ren, X., & Zeng, X. (2026). Clinical features of oxcarbazepine-associated cutaneous reactions in patients with bipolar disorder: a retrospective case series. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08621-w

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08621-w

Keywords: oxcarbazepine, bipolar disorder, cutaneous reactions, Stevens-Johnson syndrome, antiepileptic drugs, severe cutaneous adverse reactions, lamotrigine, drug hypersensitivity, case series, psychopharmacology, drug safety, dermatology